Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
FREMONT, Calif., May 03, 2018 -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release first quarter 2018 financial and operating results on Wednesday, May 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on May 9, 2018 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and corporate developments.
For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 877-591-4959. For international participants outside the U.S./Canada, the dial-in number is 719-325-2329. For all callers, refer to Conference ID 8804469. To access the live webcast, go to http://asteriasbiotherapeutics.com/inv_events_presentations.php.
A replay of the conference call will be available for one month beginning about two hours after the conclusion of the live call, by calling toll-free (from U.S./Canada) 888-203-1112 ; international callers dial 719-457-0820. Use the Conference ID 8804469. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/inv_events_presentations.php.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is an autologous cancer immunotherapy with promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML). AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The company's research partner, Cancer Research UK, plans to begin a first-in-human (FIH) clinical trial of AST-VAC2 in non-small cell lung cancer. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Contacts:
Investor Relations
(510) 456-3892
[email protected]
or
EVC Group, Inc.
Michael Polyviou/Greg Gin
(732) 232-6914
[email protected]
